SCHEMBL20577873

SCHEMBL20577873

Cc1ccc(OCCC(=O)Cl)cc1

nearest known ligand 0.70

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.70
NPC1 O15118 4/20 0.51
KMT2A Q03164 4/20 0.51
TP53 P04637 1/20 0.51
RAB9A P51151 1/20 0.51
MAPT P10636 4/20 0.50
MEN1 O00255 3/20 0.50
HPGD P15428 2/20 0.50
HTT P42858 1/20 0.49
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
DRD2 P14416 1/20 0.47
DRD4 P21917 1/20 0.47
DRD3 P35462 1/20 0.47
GAA P10253 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17431227 0.90 L3MBTL1 (0.58) L3MBTL1NPC1KMT2ATP53RAB9A
SCHEMBL27750359 0.84 L3MBTL1 (0.75) L3MBTL1NPC1KMT2ATP53RAB9A
SCHEMBL11128265 0.82 L3MBTL1 (0.72) L3MBTL1NPC1KMT2ATP53RAB9A
SCHEMBL1806524 0.82 L3MBTL1 (1.00) L3MBTL1NPC1KMT2ATP53RAB9A
SCHEMBL10609303 0.82 KMT2A (0.51) L3MBTL1NPC1KMT2ARAB9AMEN1
SCHEMBL169689 0.82 L3MBTL1 (0.72) L3MBTL1NPC1KMT2ATP53RAB9A
SCHEMBL8773638 0.81 LMNA (0.51) L3MBTL1NPC1KMT2ARAB9AMAPT
SCHEMBL1310073 0.81 LTA4H (0.50) L3MBTL1KMT2AMEN1DRD2DRD4
SCHEMBL881471 0.81 L3MBTL1 (0.70) L3MBTL1NPC1KMT2ATP53RAB9A
SCHEMBL2717154 0.80 MAPT (0.62) L3MBTL1NPC1KMT2AMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3634948-B1 INHIBITORS OF RAC1 AND USES THEREOF FOR INDUCING BRONCHODILATATION INST NAT SANTE RECH MED (FR) 2025-09-17 EP disclosed
EP-3634949-B1 INHIBITORS OF RAC1 AND USES THEREOF FOR TREATING CANCERS INST NAT SANTE RECH MED (FR) 2025-03-19 EP disclosed
US-11795144-B2 Inhibitors of RAC1 and uses thereof for treating cancers INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2023-10-24 US disclosed
US-11607419-B2 Inhibitors of RAC1 and uses thereof for inducing bronchodilatation INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) 2023-03-21 US disclosed
WO-2018224563-A9 INHIBITORS OF RAC1 AND USES THEREOF FOR TREATING CANCERS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2021-04-22 WO disclosed
US-20210077508-A1 INHIBITORS OF RAC1 AND USES THEREOF FOR INDUCING BRONCHODILATATION NANTES UNIVERSITE (FR) 2021-03-18 US disclosed
EP-3634948-A1 INHIBITORS OF RAC1 AND USES THEREOF FOR INDUCING BRONCHODILATATION Institut National de la Sante et de la Recherche Medicale (INSERM) (FR) 2020-04-15 EP disclosed
EP-3634949-A1 INHIBITORS OF RAC1 AND USES THEREOF FOR TREATING CANCERS Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) 2020-04-15 EP disclosed
US-20200095199-A1 INHIBITORS OF RAC1 AND USES THEREOF FOR TREATING CANCERS NANTES UNIVERSITE (FR) 2020-03-26 US disclosed
WO-2018224560-A1 INHIBITORS OF RAC1 AND USES THEREOF FOR INDUCING BRONCHODILATATION INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2018-12-13 WO disclosed
WO-2018224563-A1 INHIBITORS OF RAC1 AND USES THEREOF FOR TREATING CANCERS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2018-12-13 WO disclosed
EP-3412652-A1 INHIBITORS OF RAC1 AND USES THEREOF FOR TREATING CANCERS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2018-12-12 EP disclosed
EP-3412651-A1 INHIBITORS OF RAC1 AND USES THEREOF FOR INDUCING BRONCHODILATATION INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2018-12-12 EP disclosed
CN-108368102-A 2- amino -1,3,4- thiadiazines and antifungal agent based on 2- amino -1,3,4- oxadiazines F2G有限公司 2018-08-03 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11795144-B2 Inhibitors of RAC1 and uses thereof for treating cancers RAC1, KRAS, CYRIB L3MBTL1 1887/4885NPC1 1666/4885KMT2A 3254/4885
US-11607419-B2 Inhibitors of RAC1 and uses thereof for inducing bronchodilatation RAC1, CYRIB, ARHGDIB L3MBTL1 3400/4885NPC1 2075/4885KMT2A 4243/4885
US-20210077508-A1 INHIBITORS OF RAC1 AND USES THEREOF FOR INDUCING BRONCHODILATATION RAC1, CYRIB, ARHGDIB L3MBTL1 3400/4885NPC1 2075/4885KMT2A 4243/4885
US-20200095199-A1 INHIBITORS OF RAC1 AND USES THEREOF FOR TREATING CANCERS RAC1, KRAS, CYRIB L3MBTL1 1887/4885NPC1 1666/4885KMT2A 3254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.